Loading...
Header Logo
Keywords
Last Name
Institution

Dr Jeffrey Victor Ravetch

Title[no position]
Institution[no institution name]
Address[no address]
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Signaling by Antibodies: Recent Progress. Annu Rev Immunol. 2017 Apr 26; 35:285-311. PMID: 28446061.
      View in: PubMed
    2. Bournazos S, Ravetch JV. Attenuated Vaccines for Augmented Immunity. Cell Host Microbe. 2017 Mar 08; 21(3):314-315. PMID: 28279341.
      View in: PubMed
    3. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, Pinsky BA, Chokephaibulkit K, Onlamoon N, Pattanapanyasat K, Taubenberger JK, Ahmed R, Ravetch JV. IgG antibodies to dengue enhanced for Fc?RIIIA binding determine disease severity. Science. 2017 01 27; 355(6323):395-398. PMID: 28126818.
      View in: PubMed
    4. Dahan R, Ravetch JV. Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement. Cancer Cell. 2016 Sep 12; 30(3):369-71. PMID: 27622328.
      View in: PubMed
    5. Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell. 2016 Jun 16; 165(7):1609-20. PMID: 27315478; PMCID: PMC4970321 [Available on 06/16/17].
    6. Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective Fc?R Engagement. Cancer Cell. 2016 06 13; 29(6):820-31. PMID: 27265505; PMCID: PMC4975533 [Available on 06/13/17].
    7. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. Fc?Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell. 2015 Sep 14; 28(3):285-95. PMID: 26373277.
      View in: PubMed
    8. Bournazos S, DiLillo DJ, Ravetch JV. The role of Fc-Fc?R interactions in IgG-mediated microbial neutralization. J Exp Med. 2015 Aug 24; 212(9):1361-9. PMID: 26282878; PMCID: PMC4548051.
    9. Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, Schlesinger SJ, Palese P, Ahmed R, Ravetch JV. Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell. 2015 Jul 02; 162(1):160-9. PMID: 26140596; PMCID: PMC4594835.
    10. DiLillo DJ, Ravetch JV. Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. Cancer Immunol Res. 2015 Jul; 3(7):704-13. PMID: 26138698.
      View in: PubMed
    11. DiLillo DJ, Ravetch JV. Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. Cell. 2015 May 21; 161(5):1035-45. PMID: 25976835; PMCID: PMC4441863.
    12. Fiebiger BM, Maamary J, Pincetic A, Ravetch JV. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc Natl Acad Sci U S A. 2015 May 05; 112(18):E2385-94. PMID: 25870292; PMCID: PMC4426441.
    13. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014 Sep 11; 158(6):1243-53. PMID: 25215485; PMCID: PMC4167398.
    14. Ravetch JV. A full complement of receptors in immune complex diseases. J Clin Invest. 2002 Dec; 110(12):1759-61. PMID: 12488423; PMCID: PMC151658.
    15. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001; 19:275-90. PMID: 11244038.
      View in: PubMed
    Ravetch's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description